Merck KGaA eyes more manufacturing M&A as it faces headwinds in China

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales expectations for its life science …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA Investigating ‘Serious Risk’ of Malignancy After CAR-T Therapy

The FDA has launched an investigation into reports of T-cell malignancies in patients treated with autologous chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation

November 29, 2023

Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data

Share this article Gilead’s Biktarvy has previously been approved by the US FDA as HIV treatment in both adult and paediatric (weighing at least 14kg)

April 29, 2024

FDA approves Takeda’s GAMMAGARD LIQUID for CIDP treatment

Share this article The FDA granted the approval based on data from Takeda’s ADVANCE-CIDP 2 clinical trial of GAMMAGARD LIQUID. Credit: Jonathan Weiss / Shutterstock.com.

January 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.